Skip to content
2000
Volume 23, Issue 3
  • ISSN: 1568-0096
  • E-ISSN: 1873-5576

Abstract

Chimeric antigen receptor (CAR T) cell treatment for solid tumours faces significant challenges. CAR T cells are unable to pass the vascular barrier in tumours due to a lack of endothelial leukocyte adhesion molecules. The invasion, activity, and durability of CAR T cells may be hampered by additional immunosuppressive mechanisms present in the solid tumour environment. The use of CAR T cells to attack cancer vascular endothelial metabolic targets from within the blood may simplify the fight against cancer. These are the principles that govern our examination of CAR T cell treatment for tumor cells, with a specific eye toward tumour venous delivery. CAR T cells may also be designed such that they can be readily, safely, and successfully transferred.

Loading

Article metrics loading...

/content/journals/ccdt/10.2174/1568009622666220928141727
2023-03-01
2025-07-15
Loading full text...

Full text loading...

/content/journals/ccdt/10.2174/1568009622666220928141727
Loading

  • Article Type:
    Review Article
Keyword(s): angiogenesis; blood diffusion; CAR T cells; Solid tumor; targeted therapy; tumour
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test